# Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

> **NCT03420222** · PHASE2 · TERMINATED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Intermittent Explosive Disorder

## Interventions

- **DRUG:** AVP-786
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03420222
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-18
- **Primary completion:** 2018-12-28
- **Final completion:** 2018-12-28
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Due to limited enrollment (N=10), this clinical trial was terminated by the Sponsor.
- **Last updated:** 2022-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03420222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03420222, "Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03420222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*